Dino Premilovac1,2, Emily Attrill2, Stephen Rattigan1, Stephen M Richards1,2, Jeonga Kim3, Michelle A Keske1,4. 1. Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. 2. School of Medicine, University of Tasmania, Hobart, TAS, Australia. 3. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 4. Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC, Australia.
Abstract
AIMS: Angiotensin II (AngII) is a potent vasoconstrictor implicated in both hypertension and insulin resistance. Insulin dilates the vasculature in skeletal muscle to increase microvascular blood flow and enhance glucose disposal. In the present study, we investigated whether acute AngII infusion interferes with insulin's microvascular and metabolic actions in skeletal muscle. METHODS AND RESULTS: Adult, male Sprague-Dawley rats received a systemic infusion of either saline, AngII, insulin (hyperinsulinaemic euglycaemic clamp), or insulin (hyperinsulinaemic euglycaemic clamp) plus AngII. A final, separate group of rats received an acute local infusion of AngII into a single hindleg during systemic insulin (hyperinsulinaemic euglycaemic clamp) infusion. In all animals' systemic metabolic effects, central haemodynamics, femoral artery blood flow, microvascular blood flow, and skeletal muscle glucose uptake (isotopic glucose) were monitored. Systemic AngII infusion increased blood pressure, decreased heart rate, and markedly increased circulating glucose and insulin concentrations. Systemic infusion of AngII during hyperinsulinaemic euglycaemic clamp inhibited insulin-mediated suppression of hepatic glucose output and insulin-stimulated microvascular blood flow in skeletal muscle but did not alter insulin's effects on the femoral artery or muscle glucose uptake. Local AngII infusion did not alter blood pressure, heart rate, or circulating glucose and insulin. However, local AngII inhibited insulin-stimulated microvascular blood flow, and this was accompanied by reduced skeletal muscle glucose uptake. CONCLUSIONS: Acute infusion of AngII significantly alters basal haemodynamic and metabolic homeostasis in rats. Both local and systemic AngII infusion attenuated insulin's microvascular actions in skeletal muscle, but only local AngII infusion led to reduced insulin-stimulated muscle glucose uptake. While increased local, tissue production of AngII may be a factor that couples microvascular insulin resistance and hypertension, additional studies are needed to determine the molecular mechanisms responsible for these vascular defects. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Angiotensin II (AngII) is a potent vasoconstrictor implicated in both hypertension and insulin resistance. Insulin dilates the vasculature in skeletal muscle to increase microvascular blood flow and enhance glucose disposal. In the present study, we investigated whether acute AngII infusion interferes with insulin's microvascular and metabolic actions in skeletal muscle. METHODS AND RESULTS: Adult, male Sprague-Dawley rats received a systemic infusion of either saline, AngII, insulin (hyperinsulinaemic euglycaemic clamp), or insulin (hyperinsulinaemic euglycaemic clamp) plus AngII. A final, separate group of rats received an acute local infusion of AngII into a single hindleg during systemic insulin (hyperinsulinaemic euglycaemic clamp) infusion. In all animals' systemic metabolic effects, central haemodynamics, femoral artery blood flow, microvascular blood flow, and skeletal muscle glucose uptake (isotopic glucose) were monitored. Systemic AngII infusion increased blood pressure, decreased heart rate, and markedly increased circulating glucose and insulin concentrations. Systemic infusion of AngII during hyperinsulinaemic euglycaemic clamp inhibited insulin-mediated suppression of hepatic glucose output and insulin-stimulated microvascular blood flow in skeletal muscle but did not alter insulin's effects on the femoral artery or muscle glucose uptake. Local AngII infusion did not alter blood pressure, heart rate, or circulating glucose and insulin. However, local AngII inhibited insulin-stimulated microvascular blood flow, and this was accompanied by reduced skeletal muscle glucose uptake. CONCLUSIONS: Acute infusion of AngII significantly alters basal haemodynamic and metabolic homeostasis in rats. Both local and systemic AngII infusion attenuated insulin's microvascular actions in skeletal muscle, but only local AngII infusion led to reduced insulin-stimulated muscle glucose uptake. While increased local, tissue production of AngII may be a factor that couples microvascular insulin resistance and hypertension, additional studies are needed to determine the molecular mechanisms responsible for these vascular defects. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Amy M Jonk; Alfons J H M Houben; Nicolaas C Schaper; Peter W de Leeuw; Erik H Serné; Yvo M Smulders; Coen D A Stehouwer Journal: J Clin Endocrinol Metab Date: 2010-05-25 Impact factor: 5.958
Authors: Roman Metzger; Folker E Franke; Rainer M Bohle; François Alhenc-Gelas; Sergei M Danilov Journal: Microvasc Res Date: 2010-12-16 Impact factor: 3.514
Authors: M Raitakari; P Nuutila; U Ruotsalainen; H Laine; M Teräs; H Iida; S Mäkimattila; T Utriainen; V Oikonen; H Sipilä; M Haaparanta; O Solin; U Wegelius; J Knuuti; H Yki-Järvinen Journal: Diabetes Date: 1996-11 Impact factor: 9.461
Authors: Amy M Jonk; Alfons J H M Houben; Renate T de Jongh; Erik H Serné; Nicoloaas C Schaper; Coen D A Stehouwer Journal: Physiology (Bethesda) Date: 2007-08
Authors: Dominga Lapi; Maurizio Cammalleri; Massimo Dal Monte; Martina Di Maro; Mariarosaria Santillo; Anna Belfiore; Gilda Nasti; Simona Damiano; Rossella Trio; Martina Chiurazzi; Barbara De Conno; Nicola Serao; Paolo Mondola; Antonio Colantuoni; Bruna Guida Journal: Biomolecules Date: 2021-12-10